Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
PaperCitations, authors & open-access status
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 188 citations, 2017 year and closed oa status.
188
Citations
2017
Year
closed
OA Status